CDK2, cyclin dependent kinase 2, 1017

N. diseases: 270; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 AlteredExpression disease BEFREE Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population. 26828990 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 Biomarker disease BEFREE Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women. 23787073 2013
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 Biomarker disease BEFREE Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. 24004674 2013
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 AlteredExpression disease LHGDN Therefore, these results suggest that serum starvation induces G1 arrest through suppression of Skp2-dependent CDK2 activity and Skp2-independent CDK4 activity in human SK-OV-3 ovarian cancer cells. 18202766 2008
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 AlteredExpression disease BEFREE Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. 11992549 2002
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 AlteredExpression disease BEFREE The results suggest that low expression of p27(kip1) and cyclin D1 as well as high expression of cyclin E and cdk2 promotes the development of ovarian tumors. p27(kip1) and cyclin D1 expression are negatively correlated with the malignant degree of epithelial ovarian tumors. 10329035 1999
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 Biomarker disease BEFREE Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. 9426687 1998
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 Biomarker disease BEFREE These results suggest that: (i) homozygous deletion is the main mechanism of inactivation of p16/CDKN2 and p15/MTS2 in ovarian tumorigenesis; (ii) inactivation of p16/CDKN2 and p15/MTS2 may be the histological type-specific events involved in ovarian tumorigenesis; and (iii) inactivation of p16/CDKN2 is potentially involved in the progression of ovarian tumors in advanced stages. 8980248 1996
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 Biomarker disease BEFREE To establish the frequency of CDKN2 gene abnormalities in ovarian tumour specimens, we have studied this gene in five ovarian cancer cell lines and in 32 primary and five metastatic ovarian adenocarcinomas. 8855976 1996
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 Biomarker disease BEFREE We have investigated the role of the CDKN2 gene in ovarian cancer by analysis for allelic loss of 9p21 and single-strand conformational polymorphism analysis of exons 1 and 2 of CDKN2 in 67 primary ovarian tumours. 7591208 1995
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.100 GeneticVariation disease BEFREE In this aspect, the potential role of the CDKN2 gene at 9p21-p22 in ovarian carcinogenesis was assessed in an extended panel of ovarian tumors, 11 human ovarian carcinoma cell lines, and 1 cervical tumor cell line. 7743516 1995